Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1239 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Nivolumab for high risk invasive urothelial carcinoma - adjuvant	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Urothelial cancer	Urological Cancer	2019	View \| Download
Nivolumab for oesophageal or gastro-oesophageal junction cancer - adjuvant	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Gastro-oesophageal junction cancer , Oesophageal cancer	Gastrointestinal Cancer , Head and Neck Cancer	2019	View \| Download
Nivolumab for platinum-resistant advanced or recurrent ovarian cancer	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer	Female Reproductive Cancer	2019	View \| Download
Nivolumab for treating advanced clear cell renal cell carcinoma after systemic treatment	Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2024	View \| Download
Nivolumab in addition to chemotherapy for advanced gastric cancer – first line	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Gastric cancer	Gastrointestinal Cancer	2018	View \| Download
Nivolumab in addition to radiation therapy for glioblastoma – first line	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Radiation	Glioma	Neurological Cancer	2018	View \| Download
Nivolumab in addition to temozolomide and radiotherapy for MGMT-methylated glioblastoma in newly diagnosed adults - first line	Nivolumab (Opdivo; BMS-936558; ONO-4538) , Radiation , Temozolomide (Temodar; Temodal; SCH 52365)	Glioma	Neurological Cancer	2019	View \| Download
Nivolumab in combination with cabozantinib for metastatic renal cell carcinoma – first-line	Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Renal cell carcinoma (RCC)	Renal Cancer	2019	View
Nivolumab in combination with chemoradiotherapy for squamous cell head and neck cancer	Cisplatin (Platinol) , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Head and neck cancer	Head and Neck Cancer	2021	View \| Download
Nivolumab in combination with chemotherapy for early-stage non-small cell lung cancer – neoadjuvant	Chemotherapy , Nivolumab (Opdivo; BMS-936558; ONO-4538)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download